Findings

What do systematic reviews say?

288 questions · 290 findings · 74 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 56 · 19.3%GRADE not reported 21 · 7.2%Very low 61 · 21%Low 62 · 21.4%Moderate 39 · 13.4%High 51 · 17.6%

Intervention not reported

Mean baseline values. · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Intervention not reported

WDAEs within 3‐12 weeks · participants with normal or abnormal lipid profiles

It is very uncertain whether the intervention changes WDAEs within 3‐12 weeks (very low certainty).

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
RR 1.52 [0.94, 2.45]
16 studies · 3023 participants
Very low

Intervention not reported

LDL‐cholesterol fluvastatin 20 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
55 studies · 9010 participants
High

Intervention not reported

LDL‐cholesterol fluvastatin 40 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
57 studies · 3658 participants
High

Intervention not reported

LDL‐cholesterol fluvastatin 80 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
32 studies · 4928 participants
High

Intervention not reported

CI: Confidence interval · participants with normal or abnormal lipid profiles

The review found no eligible studies for this question.

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Mean baseline values. · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Intervention not reported

Total cholesterol fluvastatin 10 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 287 participants
High

Intervention not reported

Total cholesterol fluvastatin 20 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
50 studies · 6309 participants
High

Intervention not reported

Total cholesterol fluvastatin 40 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
55 studies · 2966 participants
High

Treadmill (with or without body weight support) vs other interventions

Dropouts ‐ by end of treatment Numbers of dropouts and adverse events · adults who had suffered a stroke and exhibited an abnormal gait pattern

1 finding from 1 review

Treadmill training and body weight support for walking after stroke 2017 · Cochrane Headline outcomes only
no estimate extracted
56 studies · 3105 participants
Low

Treadmill (with or without body weight support) vs other interventions

Walking speed (m/s) at end of treatment timed measures of gait · adults who had suffered a stroke and exhibited an abnormal gait pattern

1 finding from 1 review

Treadmill training and body weight support for walking after stroke 2017 · Cochrane Headline outcomes only
no estimate extracted
47 studies · 2323 participants
Moderate

Treadmill (with or without body weight support) vs other interventions

Activity Gait speed · adults who had suffered a stroke and exhibited an abnormal gait pattern

2 findings from 1 review

Treadmill training and body weight support for walking after stroke 2017 · Cochrane Headline outcomes only
no estimate extracted
9 studies · 752 participants
Low
Treadmill training and body weight support for walking after stroke 2017 · Cochrane Headline outcomes only
no estimate extracted
38 studies · 1571 participants
Low

Treadmill (with or without body weight support) vs other interventions

Walking endurance · adults who had suffered a stroke and exhibited an abnormal gait pattern

1 finding from 1 review

Treadmill training and body weight support for walking after stroke 2017 · Cochrane Headline outcomes only
no estimate extracted
28 studies · 1680 participants
Moderate

Treadmill (with or without body weight support) vs other interventions

Walking endurance (m) at end of treatment ‐ dependent in walking at start of treatment timed measures of gait · adults who had suffered a stroke and exhibited an abnormal gait pattern

1 finding from 1 review

Treadmill training and body weight support for walking after stroke 2017 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 639 participants
Low

Treadmill (with or without body weight support) vs other interventions

Walking endurance (m) at end of treatment ‐ independent in walking at start of treatment timed measures of gait · adults who had suffered a stroke and exhibited an abnormal gait pattern

1 finding from 1 review

Treadmill training and body weight support for walking after stroke 2017 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 1041 participants
Low

Intervention not reported

All‐cause mortality Median · adults older than 18 years, with no restriction regarding presence of ASCVD; participants generally had elevated risk of ASCVD (as…

The intervention showed no clear difference in all‐cause mortality Median (low certainty).

1 finding from 1 review

Fixed‐dose combination therapy for the prevention of atherosclerotic cardiovascular diseases 2017 · Cochrane Headline outcomes only
RR 1.1 [0.64, 1.89]
5 studies · 5300 participants
Low

Intervention not reported

ASCVD event, such as fatal or non‐fatal myocardial infarction or stroke. Median · adults older than 18 years, with no restriction regarding presence of ASCVD; participants generally had elevated risk of ASCVD (as…

The intervention showed no clear difference in ASCVD event, such as fatal or non‐fatal myocardial infarction or… (low certainty).

1 finding from 1 review

Fixed‐dose combination therapy for the prevention of atherosclerotic cardiovascular diseases 2017 · Cochrane Headline outcomes only
RR 1.26 [0.95, 1.66]
6 studies · 4517 participants
Low

Intervention not reported

Any investigator‐defined adverse event Median · adults older than 18 years, with no restriction regarding presence of ASCVD; participants generally had elevated risk of ASCVD (as…

The intervention probably leads to higher any investigator‐defined adverse event Median (moderate certainty).

1 finding from 1 review

Fixed‐dose combination therapy for the prevention of atherosclerotic cardiovascular diseases 2017 · Cochrane Headline outcomes only
RR 1.16 [1.09, 1.25]
11 studies · 6906 participants
Moderate

Intervention not reported

Systolic blood pressure, mmHg Median · adults older than 18 years, with no restriction regarding presence of ASCVD; participants generally had elevated risk of ASCVD (as…

1 finding from 1 review

Fixed‐dose combination therapy for the prevention of atherosclerotic cardiovascular diseases 2017 · Cochrane Headline outcomes only
no estimate extracted
13 studies · 7638 participants
Moderate